A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
NCT ID: NCT01813812
Last Updated: 2013-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
492 participants
INTERVENTIONAL
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial to Evaluate the Efficacy and Safety of DA-5219 in Patients With Acute or Chronic Gastritis
NCT06151210
A Study to Evaluate the Efficacy and Safety of DA-5204
NCT02282670
A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration
NCT07139886
Clinical Trial to Compare Rebamipide/Nizatidine Combination Therapy With Nizatidine Monotherapy in Patients With Gastritis
NCT05072938
Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo
NCT02632812
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DA-6034 45mg
two tablets (of DA-6034 45mg) are administered for 2 continuous weeks, three times a day.
DA-6034
DA-6034 90mg
two tablets (of DA-6034 90mg) are administered for 2 continuous weeks, three times a day.
DA-6034
Rebamipide 300mg
two tablets (of Rebamipide 300mg) are administered for 2 continuous weeks, three times a day.
Rebamipide 300mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DA-6034
Rebamipide 300mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1 or more erosions found in the gastroscope examination
* Age should be: 20≤age≤75
Exclusion Criteria
* Received a medication including non-steroid anti-inflammatory drug 2 weeks before the initiation
* Had a surgery regarding gastroesophageal
* A patient with Zollinger-Ellison syndrome
* Had a medical history of a malignant tumor
* A patient who is currently taking anti-thrombotic drugs
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hyun Chae Jung, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Hospital
Soo Heon Park, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Catholic University Yeouido St. Mary's Hopspital
Seong Woo Jeon, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Kyungpook National University Hospital
Sang Woo Lee, M.D.,Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Korea University Ansan Hospital
Dong Ho Lee, M.D.,Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Seoul National University Bundang Hospital
Kook Lae Lee, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
SMG-SNU Boramae Medical Center
Ju Yung Cho, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Soonchunhyang University Hospital
Ki Myeong Lee, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ajou University School of Medicine
Yongchan Lee, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Severance Hospital, Yonsei University
Sang Yong Seol, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Inje University
Jeong Seop Moon, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Inje University
Jong Sun Rew, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Chonnam National University Hospital
Soo Taek Lee, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
Chan Kook Park, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Chosun University Hospital
Jae Gyu Kim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Chung-Ang University Hosptial, Chung-Ang University College of Medicine
Sei Jin Youn, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Chungbuk National University Hospital
Hak Yang Kim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Hallym University Medical Center
Byung Chul Yoon, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Hanyang University
Suck Chei Choi, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Wonkwang University Hospital
Ki Nam Shim, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ewha Womans University Mokdong Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA6034_Gas_III (Version 4.3)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.